These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36368321)

  • 41. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.
    Fiaschetti G; Schroeder C; Castelletti D; Arcaro A; Westermann F; Baumgartner M; Shalaby T; Grotzer MA
    Acta Neuropathol Commun; 2014 Apr; 2():39. PubMed ID: 24708907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.
    Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK
    Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma.
    Folgiero V; Miele E; Carai A; Ferretti E; Alfano V; Po A; Bertaina V; Goffredo BM; Benedetti MC; Camassei FD; Cacchione A; Locatelli F; Mastronuzzi A
    Oncotarget; 2016 Aug; 7(33):52900-52911. PubMed ID: 27174915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
    Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
    J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
    Ecker J; Thatikonda V; Sigismondo G; Selt F; Valinciute G; Oehme I; Müller C; Buhl JL; Ridinger J; Usta D; Qin N; van Tilburg CM; Herold-Mende C; Remke M; Sahm F; Westermann F; Kool M; Wechsler-Reya RJ; Chavez L; Krijgsveld J; Jäger N; Pfister SM; Witt O; Milde T
    Neuro Oncol; 2021 Feb; 23(2):226-239. PubMed ID: 32822486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.
    Wang F; Remke M; Bhat K; Wong ET; Zhou S; Ramaswamy V; Dubuc A; Fonkem E; Salem S; Zhang H; Hsieh TC; O'Rourke ST; Wu L; Li DW; Hawkins C; Kohane IS; Wu JM; Wu M; Taylor MD; Wu E
    Oncotarget; 2015 Feb; 6(5):2709-24. PubMed ID: 25576913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
    Shofuda T; Kanemura Y
    Neuro Oncol; 2021 Feb; 23(2):173-174. PubMed ID: 33394043
    [No Abstract]   [Full Text] [Related]  

  • 49. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
    Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
    Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.
    Andrade AF; Borges KS; Suazo VK; Geron L; Corrêa CA; Castro-Gamero AM; de Vasconcelos EJ; de Oliveira RS; Neder L; Yunes JA; Dos Santos Aguiar S; Scrideli CA; Tone LG
    Invest New Drugs; 2017 Feb; 35(1):26-36. PubMed ID: 27785591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. B7-H6 enhances F-actin rearrangement by targeting c-MYC activation to promote medulloblastoma migration and invasion.
    Fan J; Wang Y; Liang X; Peng Y; Li S; Li X; Zhou F; Li Y
    Med Oncol; 2023 Jan; 40(3):85. PubMed ID: 36692844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth.
    Sengupta S; Weeraratne SD; Sun H; Phallen J; Rallapalli SK; Teider N; Kosaras B; Amani V; Pierre-Francois J; Tang Y; Nguyen B; Yu F; Schubert S; Balansay B; Mathios D; Lechpammer M; Archer TC; Tran P; Reimer RJ; Cook JM; Lim M; Jensen FE; Pomeroy SL; Cho YJ
    Acta Neuropathol; 2014 Apr; 127(4):593-603. PubMed ID: 24196163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models.
    Daggubati V; Hochstelter J; Bommireddy A; Choudhury A; Krup AL; Kaur P; Tong P; Li A; Xu L; Reiter JF; Raleigh DR
    J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33476305
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
    Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
    J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytotoxicity of poly-guanidine in medulloblastoma cell lines.
    Gallo-Oller G; de Ståhl TD; Alaiya A; Nilsson S; Holmberg AR; Márquez-Méndez M
    Invest New Drugs; 2023 Oct; 41(5):688-698. PubMed ID: 37556022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
    von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
    Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of Long Noncoding RNA CRNDE Increases Chemosensitivity of Medulloblastoma Cells by Targeting miR-29c-3p.
    Sun XH; Fan WJ; An ZJ; Sun Y
    Oncol Res; 2020 Feb; 28(1):95-102. PubMed ID: 31753063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
    Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
    J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.